Digitising the cell to discover new drugs
Engine Biosciences uses data analytics and machine learning to speed up the discovery of new drugs.
THE current state of medical technology has meant that despite there being some 20,000 genes in the human genome, the standard procedure for drug discovery is to laboriously measure the effect of a test drug on a single or pair of genes one by one.
Each individual or pair of genes has to be examined, which would theoretically mean conducting an excess of 20,000 tests for individual genes, and an additional 400 million tests for pairs of genes.
The trial-and-error approaches have been summarised by Engine Biosciences co-founder and chief executive officer Jeffrey Lu as: brute-force hacking or old-fashioned quests.
TRENDING NOW
MAS allocates S$1.45 billion to five asset managers in third EQDP batch: Chee Hong Tat
‘My grandfather’s legacy’: Sherman Kwek lays out three-year plan for CDL to drive returns
He built the Vingroup empire. Now South-east Asia’s richest man is handing some key roles to his sons
‘How many will survive?’: Bubble fears arise as China’s humanoid robotics face reality check
